Author Archive: David Thomas, CFA

David Thomas, CFA

David is currently Director of Industry Research and Analysis at BIO in Washington, DC. In this role, he is responsible for financial statistics and analysis of the biotechnology sector and contributes to BIO’s policy activities as well as programming for BIO’s investor conferences. Prior to joining BIO, he was a research scientist at the J. Craig Venter Institute working on the “synthetic cell” team led by Nobel Laureate Hamilton Smith. Before his role in synthetic biology, David worked as a scientist in drug discovery at Amgen, Millennium, and Novartis. His scientific expertise is in protein engineering, enzymology, and synthetic biology. David has earned the Chartered Financial Analyst (CFA) designation and holds a master’s degree in biochemistry.

Latest Posts

BIO Europe Spring 2012 – Opening Remarks

For Monday’s Opening Remarks at BIO Europe Spring 2012, I covered the following topics: Public market performance in the US vs other sectors Private funding environment. Drug pipeline deal volume. For a copy of the slides, they can be found here.

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , ,

Does Biotech History Repeat?

IPO-windows-btn

According to Mark Twain, “History does not repeat itself, but it does rhyme”. Little did he know that one day that would hold true for something called “Biotech”. Indeed, there seems to be a lot of rhyming going on with Biotech IPOs today with recent history. When we compare the accumulated number of IPOs in the last IPO window (2003-2007) with the current window (2009-now), we see an amazing overlay. Not identical, but not too far from it. Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Update: Indices, IPOs, and New Drug Approvals

Index-Feb-29th-2012-no-border-thumb

Here is a look at year to date (YTD) numbers through the end of February for the biotech indices, initial public offerings, and recent FDA Approvals. 1. Indices: The Nasdaq Biotech Index held the January jump through February, settling at + 14% YTD. The concentrated BTK slipped in February, but has outpaced the NBI since January 1st. YTD, both biotech indices have significantly outperformed the broader market. In contrast, the NYSE Pharmaceuticals Index has not Read More >

Inside BIO Industry Analysis  |  1 Comment  |  Email This Post
Tags: , , ,

Oncology Clinical Trials – Secrets of Success

Graph

At last year’s BIO CEO & Investor Conference, BIO and BioMedTracker presented data showing that drugs in development for oncology indications had the lowest overall clinical trial success rate of all therapeutic areas in development since 2004. We have updated these numbers to include clinical trials through December 2011. Although overall success rates did improve slightly, oncology remained in last place. The chart below illustrates why oncology’s overall success rate is so low relative to Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , ,

BIO CEO 2012 Opening Remarks

The 14th Annual BIO CEO & Investor Conference started with a busy turnout Monday at the Waldorf=Astoria Hotel in New York City. Meetings scheduled between institutional investors and biotech executives hit a record high and the opening plenary was a standing room only event. Kicking off the plenary were opening remarks from BIO’s Executive Vice President of Emerging Companies and Business Development, Alan Eisenberg. A copy of the slides can be found here: Opening Plenary Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , ,